NEW YORK, Oct. 30 - Myriad Genetics and drug giant Pharmacia have entered into a pharmacogenomics alliance that has been designed ultimately to develop and commercialize technologies to help researchers begin to apply personalized medicine, Myriad said on Tuesday.

Terms of the alliance, which is open-ended, call for Myriad, of Salt Lake City, to use its gene-sequencing technology to analyze SNPs from a variety of populations, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.